March 26, 2025 02:29 PM EDT

Exelixis’ primary cancer drug wins FDA approval for neuroendocrine tumors

Max Bayer

Pharma Reporter

The FDA has approved Exelixis’ cancer drug Cabometyx to treat advanced neuroendocrine tumors inside and outside of the pancreas, marking two new indications for the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exelixis’ primary cancer drug wins FDA approval for neuroendocrine tumors

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Federal judge nixes FDA's lab-developed test rule, says it exceeded agency's authority

What’s next after Marks? At FDA, questions over more top exits and future vision for drug agency

Marks’ exit at FDA rattles an already teetering biotech industry

Merck’s PAH drug cuts risk of serious events by 76% in trial stopped for efficacy

Tenaya to lay off about one-third of staff, reveals heart gene therapy data

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

Ex­elix­is’ pri­ma­ry can­cer drug wins FDA ap­proval for neu­roen­docrine tu­mors

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Fed­er­al judge nix­es FDA's lab-de­vel­oped test rule, says it ex­ceed­ed agen­cy's au­thor­i­ty

What’s next af­ter Marks? At FDA, ques­tions over more top ex­its and fu­ture vi­sion for drug agency

Marks’ ex­it at FDA rat­tles an al­ready tee­ter­ing biotech in­dus­try

Mer­ck’s PAH drug cuts risk of se­ri­ous events by 76% in tri­al stopped for ef­fi­ca­cy

Tenaya to lay off about one-third of staff, re­veals heart gene ther­a­py da­ta

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

Exelixis’ primary cancer drug wins FDA approval for neuroendocrine tumors

Federal judge nixes FDA's lab-developed test rule, says it exceeded agency's authority

What’s next after Marks? At FDA, questions over more top exits and future vision for drug agency

Marks’ exit at FDA rattles an already teetering biotech industry

Merck’s PAH drug cuts risk of serious events by 76% in trial stopped for efficacy

Tenaya to lay off about one-third of staff, reveals heart gene therapy data

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO